A Tale Of Two Targeted Therapies
This article was originally published in RPM Report
Executive Summary
FDA’s oncology office director suggests Ariad’s ponatinib and ChemGenex’s Omapro represent the best and worst of times, respectively, in the quality of development programs for personalized medicines.
You may also be interested in...
Complexities of Precision Medicine: Managing Multiple Rx/Dx Combos in the Same Class
What happens when multiple targeted therapies are approved by FDA, each with a unique companion diagnostic for the same biomarker? The health care system is ill-equipped to deal with that scenario, putting patients at risk if the wrong test is used to guide a treatment decision. Industry has one solution: an analytical comparison of various diagnostic assays, starting with the anti-PD-L1 immunotherapy class.
Ariad Prepares For Early Launch Of CML Drug Ponatinib
After filing a rolling submission for accelerated approval for wholly-owned Bcr-Abl inhibitor ponatinib in late July, Ariad plans to build a full commercial operation in the U.S. by the end of October.
No Additional Omapro Trials Needed, FDA Tells ChemGenex In Complete Response Letter
FDA reservations mirror those outlined about need for validated assay test at March 22 ODAC meeting.